We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Aripiprazole in l-dopa-induced dyskinesias: a one-year open-label pilot study.
- Authors
Meco, Giuseppe; Stirpe, Paola; Edito, Fabrizio; Purcaro, Carlo; Valente, Marcella; Bernardi, Silvia; Vanacore, Nicola
- Abstract
Aripiprazole is a novel antipsychotic medication characterized by partial agonism at the D2 and 5-HT1A receptors and by antagonism at the 5-HT2A receptor. The aim of the present study was to evaluate, in an open-label pilot study, the effects and safety of very small doses of aripiprazole on l-dopa-induced dyskinesia of a group of PD patients who did not show a significant clinical benefit by pharmacological treatment with amantadine and mirtazapine. Twelve PD patients with peak-dose LID were enrolled in a period of 1 year. Aripiprazole dosage was of 0.625 mg/day. The ten patients who continued taking aripiprazole displayed a significant decrease in the intensity and frequency of dyskinesias in all parts of the body, particularly in trunk movements (AIMS score T0 = 14.1 ± 3.6 vs. final score 2.4. ± 2.6; P = 0.005). Our study suggests that aripiprazole at very low doses is tolerated and could be efficacy in treating LID.
- Subjects
ANTIPSYCHOTIC agents; TARDIVE dyskinesia; DRUG receptors; DRUG dosage; DRUG antagonism; DOPA; AMANTADINE; DRUG efficacy
- Publication
Journal of Neural Transmission, 2009, Vol 116, Issue 7, p881
- ISSN
0300-9564
- Publication type
Article
- DOI
10.1007/s00702-009-0231-z